Clinical Trial Update: Dupilumab for Aspirin-exacerbated Respiratory Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update for dupilumab in aspirin-exacerbated respiratory disease (AERD) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspirin-exacerbated Respiratory Disease

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Rochester General Hospital | Conditions: Aspirin-exacerbated Respiratory Disease | Phase 2 | Status: COMPLETED